DealsJun 11, 2026, 08:04 AM
60 Degrees Pharma Licenses Patent for Castanospermine Extraction
AI Summary
60 Degrees Pharmaceuticals announced a patent licensing agreement with Florida State University, enabling large-scale extraction of castanospermine from Australian Chestnut seeds for non-prescription uses. Concurrently, the company will meet with the FDA on July 1, 2026, to discuss a Non-Notification Letter concerning its New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract, aiming to clarify safety information and submit a revised NDIN.
Key Highlights
- 60 Degrees Pharma executed a patent licensing agreement with Florida State University.
- License allows large-scale extraction of castanospermine from Castanospermum australe seeds.
- Castanospermine is for non-prescription uses, modulating carbohydrate metabolism at low doses.
- Company to meet with FDA on July 1, 2026, regarding a Non-Notification Letter.
- Meeting will discuss feedback on New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract.
- Company will submit a revised NDIN after clarifying safety information with FDA.
Price Impact
More from SXTP